The narrow path to CD8+ T cell recognition of mutant p53
Immunity · 2026
DOI: 10.1016/j.immuni.2026.09.020 ↗Kurz gefasst
Kommentar in der Zeitschrift Immunity, 2026. Verfasst von Evan W Newell. Beteiligte Einrichtung: Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: enewell@fredhutch.org. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, CD8-Positive T-Lymphocytes, Neoplasms. Die Arbeit nennt 10 Literaturangaben. Gefördert von: National Institutes of Health.
Abstract (Originalsprache)
Shared cancer driver mutations offer attractive targets for cancer immunotherapy, but their expression does not necessarily put them within the reach of a T cell response. In this issue of Immunity, Haratani et al. identify distinct barriers to the processing, presentation, and recognition of neoantigens generated from mutant p53 that help explain this gap.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA, USA. Electronic address: enewell@fredhutch.org.
Förderung
- National Institutes of Health
Zitieren
APA
Newell, E. W. (2026). The narrow path to CD8+ T cell recognition of mutant p53. Immunity. https://doi.org/10.1016/j.immuni.2026.09.020
Vancouver
Newell EW. The narrow path to CD8+ T cell recognition of mutant p53. Immunity. 2026. doi:10.1016/j.immuni.2026.09.020
BibTeX
@article{Newell2026,
author = {Newell, Evan W},
title = {The narrow path to CD8+ T cell recognition of mutant p53},
journal = {Immunity},
year = {2026},
doi = {10.1016/j.immuni.2026.09.020}
}
EUVIMED